208 filings
Page 7 of 11
8-K
btwp3h83zwriqw4a
2 Oct 14
Departure of Directors or Certain Officers
12:00am
8-K
b49ufvp9lixu0uvjnhxr
1 Oct 14
Other Events
12:00am
8-K
4nww87
17 Sep 14
IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference
12:00am
8-K
fm8gs 5y0h1h7
21 Aug 14
IntelGenx to Present at the Rodman & Renshaw Global Investment Conference
12:00am
8-K
tgw84uv1gu5r g6
18 Jul 14
Other Events
12:00am
8-K
yd0ps k1ukey
15 Jul 14
IntelGenx Announces Management Changes
12:00am
8-K
yqw 1unjd9
1 Jul 14
IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright
12:00am
8-K
cu0 674q25
21 May 14
Other Events
12:00am
8-K
r28hekwg9pem93 ek7
8 May 14
Submission of Matters to a Vote of Security Holders
12:00am
8-K
larucp
30 Apr 14
IntelGenx Announces Government of Canada Funding for CNS VersaFilm™ Project
12:00am
8-K
8rwgrtn7qu
28 Apr 14
Other Events
12:00am
8-K
p5zgff5
24 Apr 14
IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm™ Product
12:00am
8-K
azpctxmskf ajf
16 Apr 14
IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology
12:00am
8-K
t4t65
3 Mar 14
Other Events
12:00am
8-K
lbrpjme
26 Feb 14
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related To Proprietary Technology
12:00am
8-K
jnr4jx7w
24 Feb 14
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm™ Tadalafil Product
12:00am
8-K
numml9jd0odv8j
21 Feb 14
Regulation FD Disclosure
12:00am
8-K
2ueqh yc0o8tib4sfoob
4 Feb 14
IntelGenx and RedHill Biopharma Receive Complete Response Letter from FDA for VersaFilm™ Oral Film Product for Acute Migraines
12:00am
8-K
847u6g9u1y8ohmny4ts
13 Jan 14
IntelGenx Announces Additional Development And Commercialization Agreement With Par Pharmaceutical, Inc. For Two More Products
12:00am
8-K
vi09y
16 Dec 13
IntelGenx Closes $3.5 Million Public Offering
12:00am